ChemRxiv · 2020 · 15 citations · 34 references
MedicineMolecular BiologyOncologyCell SignalingMolecular OncologyOncogenesCancer Cell SignalingOncogene ActivationOncogene MutationsOncogenic Signaling PathwaysRas Family OncogenesSignal Transduction In CancerEnzyme-mediated DegradationKras G12c InhibitionKras InhibitorsKras-targeted TherapyMapk SignalingMitogen-activated Protein Kinase Inactivation
We report the development of LC-2, the first PROTAC capable of degrading endogenous KRAS G12C . LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines. LC-2 demonstrates that PROTAC-mediated degradation is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.
34
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text
Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences · 2001 · 2.5K citations · Full text
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations
Medicine, Oncology, Pharmacology +14
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science · 2010 · 2.1K citations